SPARQL | HTML Microdata document
This HTML5 document contains 31 embedded RDF statements represented using HTML+Microdata notation.
The embedded RDF content will be recognized by any processor of HTML5 Microdata.
Namespace Prefixes
Prefix IRI
n7 http://linked.opendata.cz/resource/mesh/concept/
rdfs http://www.w3.org/2000/01/rdf-schema#
rdf http://www.w3.org/1999/02/22-rdf-syntax-ns#
n6 http://linked.opendata.cz/ontology/mesh/
owl http://www.w3.org/2002/07/owl#
nci http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n5 http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdh http://www.w3.org/2001/XMLSchema#
Statements
Subject Item nci:C404
rdf:type
owl:Class
rdfs:label
Cycloleucine
rdfs:subClassOf
nci:C574
nci:A8
nci:C63923
nci:P106
Pharmacologic Substance
Amino Acid, Peptide, or Protein
nci:P108
Cycloleucine
nci:P175
1026
nci:P207
C0010575
nci:P210
52-52-8
nci:P319
0TQU7668EI
nci:P322
FDA
nci:P329
39200
nci:P330
39200
nci:P350
C6H11NO2
nci:P366
Cycloleucine
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>CB 1639</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0001026</n0:source-code></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ACPC</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0001026</n0:source-code></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Cycloleucine</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0001026</n0:source-code></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>1-Aminocyclopentanecarboxylic acid</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0001026</n0:source-code></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>1-Aminocyclopentane</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Cycloleucine</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>CB-1639</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ACPC</n0:term-name><n0:term-group>AB</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>CYCLOLEUCINE</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>0TQU7668EI</n0:source-code></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>1-aminocyclopentanecarboxylic acid</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ACP</n0:term-name><n0:term-group>AB</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A non-metabolizable synthetic amino acid, formed through the cyclization of the amino acid leucine, with immunosuppressive, antineoplastic, and cytostatic activities. Cycloleucine competitively inhibits the enzyme methionine adenosyltransferase, resulting in the inhibition of S-adenosylmethionine (SAM) synthesis from methionine and ATP, and subsequent nucleic acid methylation and polyamine production; RNA, and perhaps to a lesser extent, DNA biosyntheses and cell cycle progression are finally disrupted. This agent is also a competitive inhibitor at the glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C404
owl:sameAs
n5:N0000170255
n6:hasConcept
n7:M0005476